Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Int J Mol Sci. 2024 Jul 18;25(14):7856. doi: 10.3390/ijms25147856.
The association between high-density lipoprotein cholesterol (HDL-C) and cardiovascular disease (CVD) is controversial. HDL-C is one content type of high-density lipoprotein (HDL). HDL consists of diverse proteins and lipids and can be classified into different subclasses based on size, shape, charge, and density, and can change dynamically in disease states. Therefore, HDL-C levels alone cannot represent HDLs' cardioprotective role. In this review, we summarized the methods for separating HDL subclasses, the studies on the association between HDL subclasses and cardiovascular risk (CVR), and the impact of lipid-modifying medications and nonpharmacological approaches (exercise training, dietary omega fatty acids, and low-density lipoprotein apheresis) on HDL subclasses. As HDL is a natural nanoplatform, recombinant HDLs (rHDLs) have been used as a delivery system in vivo by loading small interfering RNA, drugs, contrast agents, etc. Therefore, we further reviewed the HDL subclasses used in rHDLs and their advantages and disadvantages. This review would provide recommendations and guidance for future studies on HDL subclasses' cardioprotective roles.
高密度脂蛋白胆固醇(HDL-C)与心血管疾病(CVD)之间的关联存在争议。HDL-C 是高密度脂蛋白(HDL)的一种类型。HDL 由多种蛋白质和脂质组成,可以根据大小、形状、电荷和密度进行分类,并在疾病状态下动态变化。因此,HDL-C 水平本身并不能代表 HDL 的心脏保护作用。在这篇综述中,我们总结了分离 HDL 亚类的方法、HDL 亚类与心血管风险(CVR)之间的关联研究,以及脂质调节药物和非药物方法(运动训练、饮食 ω 脂肪酸和低密度脂蛋白吸附)对 HDL 亚类的影响。由于 HDL 是一种天然的纳米平台,重组高密度脂蛋白(rHDLs)已被用作体内输送系统,通过装载小干扰 RNA、药物、造影剂等。因此,我们进一步综述了用于 rHDLs 的 HDL 亚类及其优缺点。这篇综述将为未来研究 HDL 亚类的心脏保护作用提供建议和指导。